310 related articles for article (PubMed ID: 24520328)
1. Chimeric antibody c.8B6 to O-acetyl-GD2 mediates the same efficient anti-neuroblastoma effects as therapeutic ch14.18 antibody to GD2 without antibody induced allodynia.
Terme M; Dorvillius M; Cochonneau D; Chaumette T; Xiao W; Diccianni MB; Barbet J; Yu AL; Paris F; Sorkin LS; Birklé S
PLoS One; 2014; 9(2):e87210. PubMed ID: 24520328
[TBL] [Abstract][Full Text] [Related]
2. A monoclonal antibody to O-acetyl-GD2 ganglioside and not to GD2 shows potent anti-tumor activity without peripheral nervous system cross-reactivity.
Alvarez-Rueda N; Desselle A; Cochonneau D; Chaumette T; Clemenceau B; Leprieur S; Bougras G; Supiot S; Mussini JM; Barbet J; Saba J; Paris F; Aubry J; Birklé S
PLoS One; 2011; 6(9):e25220. PubMed ID: 21966461
[TBL] [Abstract][Full Text] [Related]
3. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice.
Zeng Y; Fest S; Kunert R; Katinger H; Pistoia V; Michon J; Lewis G; Ladenstein R; Lode HN
Mol Immunol; 2005 Jul; 42(11):1311-9. PubMed ID: 15950727
[TBL] [Abstract][Full Text] [Related]
4. Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD
Mueller I; Ehlert K; Endres S; Pill L; Siebert N; Kietz S; Brock P; Garaventa A; Valteau-Couanet D; Janzek E; Hosten N; Zinke A; Barthlen W; Varol E; Loibner H; Ladenstein R; Lode HN
MAbs; 2018 Jan; 10(1):55-61. PubMed ID: 29120699
[TBL] [Abstract][Full Text] [Related]
5. Validated detection of anti-GD2 antibody ch14.18/CHO in serum of neuroblastoma patients using anti-idiotype antibody ganglidiomab.
Siebert N; Seidel D; Eger C; Brackrock D; Reker D; Schmidt M; Lode HN
J Immunol Methods; 2013 Dec; 398-399():51-9. PubMed ID: 24055592
[TBL] [Abstract][Full Text] [Related]
6. Electrophysiological characteristics of primary afferent fibers after systemic administration of anti-GD2 ganglioside antibody.
Xiao WH; Yu AL; Sorkin LS
Pain; 1997 Jan; 69(1-2):145-51. PubMed ID: 9060025
[TBL] [Abstract][Full Text] [Related]
7. Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment.
Seitz CM; Flaadt T; Mezger M; Lang AM; Michaelis S; Katz M; Syring D; Joechner A; Rabsteyn A; Siebert N; Troschke-Meurer S; Zumpe M; Lode HN; Yang SF; Atar D; Mast AS; Scheuermann S; Heubach F; Handgretinger R; Lang P; Schlegel P
Front Immunol; 2021; 12():690467. PubMed ID: 34367149
[TBL] [Abstract][Full Text] [Related]
8. Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma.
Seidel D; Shibina A; Siebert N; Wels WS; Reynolds CP; Huebener N; Lode HN
Cancer Immunol Immunother; 2015 May; 64(5):621-34. PubMed ID: 25711293
[TBL] [Abstract][Full Text] [Related]
9. Inflammatory response and treatment tolerance of long-term infusion of the anti-GD
Ceylan K; Jahns LJ; Lode BN; Ehlert K; Kietz S; Troschke-Meurer S; Siebert N; Lode HN
Pediatr Blood Cancer; 2018 Jun; 65(6):e26967. PubMed ID: 29350486
[TBL] [Abstract][Full Text] [Related]
10. Validated detection of human anti-chimeric immune responses in serum of neuroblastoma patients treated with ch14.18/CHO.
Siebert N; Eger C; Seidel D; Jüttner M; Lode HN
J Immunol Methods; 2014 May; 407():108-15. PubMed ID: 24727144
[TBL] [Abstract][Full Text] [Related]
11. SIRPα-specific monoclonal antibody enables antibody-dependent phagocytosis of neuroblastoma cells.
Bahri M; Kailayangiri S; Vermeulen S; Galopin N; Rossig C; Paris F; Fougeray S; Birklé S
Cancer Immunol Immunother; 2022 Jan; 71(1):71-83. PubMed ID: 34023958
[TBL] [Abstract][Full Text] [Related]
12. Superantigen-staphylococcal-enterotoxin-A-dependent and antibody-targeted lysis of GD2-positive neuroblastoma cells.
Holzer U; Bethge W; Krull F; Ihle J; Handgretinger R; Reisfeld RA; Dohlsten M; Kalland T; Niethammer D; Dannecker GE
Cancer Immunol Immunother; 1995 Aug; 41(2):129-36. PubMed ID: 7656271
[TBL] [Abstract][Full Text] [Related]
13. Neutrophils are cytotoxic and growth-inhibiting for neuroblastoma cells with an anti-GD2 antibody but, without cytotoxicity, can be growth-stimulating.
Chen RL; Reynolds CP; Seeger RC
Cancer Immunol Immunother; 2000 Feb; 48(11):603-12. PubMed ID: 10663607
[TBL] [Abstract][Full Text] [Related]
14. Molecular characterization of the anti-idiotypic immune response of a relapse-free neuroblastoma patient following antibody therapy: a possible vaccine against tumors of neuroectodermal origin?
Uttenreuther-Fischer MM; Krüger JA; Fischer P
J Immunol; 2006 Jun; 176(12):7775-86. PubMed ID: 16751426
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study.
Ozkaynak MF; Sondel PM; Krailo MD; Gan J; Javorsky B; Reisfeld RA; Matthay KK; Reaman GH; Seeger RC
J Clin Oncol; 2000 Dec; 18(24):4077-85. PubMed ID: 11118469
[TBL] [Abstract][Full Text] [Related]
16. Comparison of pain outcomes between two anti-GD2 antibodies in patients with neuroblastoma.
Anghelescu DL; Goldberg JL; Faughnan LG; Wu J; Mao S; Furman WL; Santana VM; Navid F
Pediatr Blood Cancer; 2015 Feb; 62(2):224-228. PubMed ID: 25382742
[TBL] [Abstract][Full Text] [Related]
17. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.
Parsons K; Bernhardt B; Strickland B
Ann Pharmacother; 2013 Feb; 47(2):210-8. PubMed ID: 23386066
[TBL] [Abstract][Full Text] [Related]
18. Ocular symptoms in children treated with human-mouse chimeric anti-GD2 mAb ch14.18 for neuroblastoma.
Kremens B; Hero B; Esser J; Weinel P; Filger-Brillinger J; Fleischhack G; Graf N; Grüttner HP; Niemeyer C; Schulz A; Wickmann L; Berthold F
Cancer Immunol Immunother; 2002 Apr; 51(2):107-10. PubMed ID: 11904735
[TBL] [Abstract][Full Text] [Related]
19. IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models.
Stip MC; Evers M; Nederend M; Chan C; Reiding KR; Damen MJ; Heck AJR; Koustoulidou S; Ramakers R; Krijger GC; de Roos R; Souteyrand E; Cornel AM; Dierselhuis MP; Jansen M; de Boer M; Valerius T; van Tetering G; Leusen JHW; Meyer-Wentrup F
J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37479484
[TBL] [Abstract][Full Text] [Related]
20. Anti-GD(2) with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia.
Sorkin LS; Otto M; Baldwin WM; Vail E; Gillies SD; Handgretinger R; Barfield RC; Yu HM; Yu AL
Pain; 2010 Apr; 149(1):135-142. PubMed ID: 20171010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]